Figure 2.
Survival analysis of the time to drug discontinuation due to SLR or SAE (A) and time to surgery for IBD (B). The dotted line and the solid line represent the ‘TDM never tested’ and the ‘TDM tested’ group, respectively. IBD, inflammatory bowel disease; IFX, infliximab; SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.